Hymecromone

A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.

Also Known As:

Networked: 13 relevant articles (2 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Lokeshwar, Vinata B: 2 articles (07/2015 - 07/2013)
2.	Yates, Travis J: 2 articles (07/2015 - 07/2013)
3.	Jordan, Andre: 1 article (07/2015)
4.	Ortiz, Nicolas: 1 article (07/2015)
5.	Kallifatidis, Georgios: 1 article (07/2015)
6.	Lokeshwar, Soum D: 1 article (07/2015)
7.	Lopez, Luis E: 1 article (07/2015)
8.	Altman, Norman: 1 article (07/2015)
9.	Hoye, Kelly: 1 article (07/2015)
10.	Nagy, Nadine: 1 article (01/2015)

Related Diseases

1.	Renal Cell Carcinoma (Grawitz Tumor) 07/01/2013 - "To our knowledge this is the first study to show that the combination of sorafenib and the nontoxic dietary supplement hymecromone is highly effective for controlling renal cell carcinoma." 07/01/2013 - "In the current study we examined the antitumor properties of hymecromone, sorafenib and the combination in renal cell carcinoma models. " 07/01/2013 - "Hymecromone plus sorafenib synergistically inhibited proliferation (greater than 95%), motility/invasion (65%) and capillary formation (76%) in renal cell carcinoma and/or endothelial cells, and induced apoptosis eightfold (p <0.001). " 07/01/2013 - "Using proliferation, clonogenic and apoptosis assays, we examined the effects of hymecromone (0 to 32 μg/ml), sorafenib (0 to 3.2 μg/ml) and hymecromone plus sorafenib in Caki-1, 786-O, ACHN and A498 renal cell carcinoma cells, and HMVEC-L and HUVEC endothelial cells. " 07/01/2013 - "Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma."
2.	Pain (Aches) 01/01/2001 - "Control of dyspepsia and pain symptoms of biliary origin was more marked and constant with hymecromone than with placebo. " 11/01/1996 - "An abnormal emptying pattern of the gallbladder was identified in patients with acalculous biliary colic, and hymecromone was partly effective to reduce pain, despite a minor effect on gallbladder emptying pattern." 01/01/1986 - "The results showed that tiropramide was significantly more effective in decreasing the number of attacks of pain and in improving pain and dyspepsia symptoms than imecromone. "
3.	Neoplasms (Cancer) 07/01/2013 - "Oral administration of hymecromone (50 to 200 mg/kg) plus sorafenib (30 mg/kg) eradicated Caki-1 tumor growth without toxicity. " 07/01/2013 - "Hymecromone inhibits the synthesis of hyaluronic acid, which promotes tumor growth and metastasis. " 06/01/2005 - "The mean+/-SD of beta-glucuronidase, beta-galactosidase, and alpha-mannosidase activity in the gynecologic cancers was 120+/-50 nmol, 203+/-86 nmol, and 240+/-119 nmol 4-methylumbelliferone/ml/h, respectively; in the normal control subjects it was 22+/-9 nmol, 46+/-10 nmol, and 80+/-23 nmol, respectively (P=0.00003, 0.0001, and 0.0001, respectively). "
4.	Dyspepsia (Indigestion) 01/01/2001 - "Control of dyspepsia and pain symptoms of biliary origin was more marked and constant with hymecromone than with placebo. " 01/01/1986 - "The results showed that tiropramide was significantly more effective in decreasing the number of attacks of pain and in improving pain and dyspepsia symptoms than imecromone. "
5.	Biliary Dyskinesia 01/01/1986 - "A controlled trial was carried out in patients with biliary dyskinesia to compare the effects of the new calmodulin-independent and antispastic drug tiropramide with those of imecromone. "

Related Drugs and Biologics

1.	sorafenib (BAY 43-9006)
2.	tiropramide
3.	Calmodulin (Calcium-Dependent Activator Protein)
4.	alpha-Mannosidase (LAMAN)
5.	Hymecromone
6.	Hyaluronic Acid (Hyaluronan)
7.	Glucuronidase
8.	beta-Galactosidase (Lactaid)
9.	Peptide Hydrolases (Proteases)
10.	zoledronic acid (zoledronate)

Related Therapies and Procedures

1.	Oral Administration